“…Following up on the demonstration that the ErasmusLadder enables the differentiation between cerebellar mutants in cross sectional studies (Van Der Giessen et al, 2008; Renier et al, 2010; Schonewille et al, 2011; van der Vaart et al, 2011; Baudouin et al, 2012; Saab et al, 2012; Vinueza Veloz et al, 2012; Galliano et al, 2013; Marques et al, 2015; Vinueza Veloz et al, 2015; Ha et al, 2016; Peter et al, 2016; Rahmati et al, 2016; French et al, 2018; Prekop et al, 2018; Sathyanesan et al, 2018; Sayed-Zahid et al, 2019; Wu et al, 2019; Almeida et al, 2020; Grasselli et al, 2020; Haify et al, 2020; Namdar et al, 2020; Peter et al, 2020; Blot et al, 2021; Lang-Ouellette et al, 2021; Vacher et al, 2021; White et al, 2021; Kaiser et al, 2022; Klomp et al, 2022; Lauffer et al, 2022; Ottenhoff et al, 2022; Birkisdóttir et al, 2023a; Fang et al, 2023) (Table S1), in this study we aimed to probe the ErasmusLadder as a tool for quantifying disease onset and progression in cerebellar disease models. We examined two mouse lines displaying progressive Purkinje cell degeneration, and followed their behavioral performance from early to severe symptomatic stages.…”